Pharmacotherapy of juvenile rheumatoid arthritis.
Salicylate is the drug of first choice in the initial treatment of juvenile rheumatoid arthritis. In therapeutic dosage it will adequately control joint symptoms in the majority of patients. For children who do not respond to or are intolerant of salicylate, a change to one of the other nonsteroidal anti-inflammatory agents is appropriate. In progressive polyarthritis unresponsive to the above agents, the addition of gold, antimalarials, or penicillamine is indicated, preferably in that order. Corticosteroid therapy should be reserved for selected patients meeting specific criteria. Pharmacotherapy of juvenile rheumatoid arthritis should always be individualized. For optimal treatment of the whole child it must be combined with both physical and educational measures.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D003692:Delayed-Action Preparations; D006046:Gold / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage; D007213:Indomethacin / Q000008:administration & dosage; D010396:Penicillamine / Q000627:therapeutic use; D012459:Salicylates / Q000009:adverse effects / Q000627:therapeutic use; D013467:Sulindac / Q000008:administration & dosage; D014046:Tolmetin / Q000008:administration & dosage
D000305:Adrenal Cortex Hormones; D000962:Antimalarials; D003692:Delayed-Action Preparations; D012459:Salicylates; D013467:Sulindac; D006046:Gold; D014046:Tolmetin; D010396:Penicillamine; D007052:Ibuprofen; D007213:Indomethacin